Protein / target
D-alanyl-D-alanine carboxypeptidase DacA
Protein at a glance
Biological role
Serine-type D-Ala-D-Ala carboxypeptidase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors
Subcellular location
Domains and Gene Ontology detail (13)Hide
Gene Ontology
- Couter membrane-bounded periplasmic space
- Cplasma membrane
- Fbeta-lactamase activity
- Fcarboxypeptidase activity
- Fpenicillin binding
- Fprotein homodimerization activity
- Fserine-type D-Ala-D-Ala carboxypeptidase activity
- Pcell division
- Pcell wall organization
- Ppeptidoglycan biosynthetic process
- Ppeptidoglycan metabolic process
- Pproteolysis
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Proteolysis
- ·carboxypeptidase activity
- ·serine-type D-Ala-D-Ala carboxypeptidase activity
- ·proteolysis
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections, Eye Infections, Gonorrhea, Infections
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections, Gonorrhea, Infections, Otitis Media
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections, Gonorrhea, Infections, Otitis Media
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections, Urinary Tract Infections
Bacterial penicillin-binding protein inhibitor
Indicated for Bacterial Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 5 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Geisinger Antibiotic Allergy Pilot Program: Assess and Address (GAAP) Penicillin Allergy De-labeling in Inpatient Setting by Performing Direct Oral Amoxicillin Challenge in Low-risk Patients
- Label change
Label change: AMOXICILLIN AND CLAVULANATE POTASSIUM (NDA050575)
- Label change
Label change: AMOXICILLIN AND CLAVULANATE POTASSIUM (NDA050720)
- Label change
Label change: AMOXICILLIN AND CLAVULANATE POTASSIUM (NDA050755)
- Label change
Label change: AMOXICILLIN AND CLAVULANATE POTASSIUM (NDA050785)
- Label change
Label change: AMOXICILLIN AND CLAVULANATE POTASSIUM (NDA050755)
- Product recall
Recall (Class II): CEFIXIME
- New publicationCefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
- New publicationAntibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism.
- New publicationCorticosteroids for pneumonia.
- New publicationManagement of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
- Safety communication
Drug Safety Update: Doripenem (Doribax▼): updated dosing recommendations
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.